Evidence map›Paper›PMID 40911431›Full record

ArticleACS applied materials & interfaces2025

Cu-Mn Bimetallic Mesoporous Silica Nanosonosensitizers Enable Oxeiptosis-Mediated Sonodynamic Therapy for Ultra-Minimally Invasive Treatment of Benign Prostatic Hyperplasia.

Mingyu Chang, Jingcheng Lv, Lianhui Sun, Aihong Chen, Fengbo Zhang, Guangjian Fan, Zhanliang Liu, Jun Li, Hongliang Shen, Mingjun Shi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Oxeiptosis - potential in cancer treatment?Expert reviews in molecular medicine · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mingyu ChangDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Jingcheng LvDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Lianhui SunDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Aihong ChenCollege of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China.
Fengbo ZhangDepartment of Urology, Beijing Luhe Hospital, Capital Medical University, Beijing 101199, China.
Guangjian FanPrecision Research Center for Refractory Diseases, Institute for Clinical Research, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Zhanliang LiuDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Jun LiDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Hongliang ShenDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Mingjun ShiDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Yinong NiuDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Ye TianDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Xijian LiuCollege of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China.ORCID 0000-0001-5856-9142
Boyu YangDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.ORCID 0000-0002-0222-8071

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign prostatic hyperplasia (BPH) presents a significant clinical challenge, with conventional therapies carrying substantial risks, including urinary retention, sexual dysfunction, and prolonged recovery. To address the urgent need for safer, ultra-minimally invasive alternatives, we developed a sonosensitizing nanoplatform using copper-manganese-doped mesoporous silica nanoparticles (Cu-Mn@SiO

Indexed as

CopperManganeseNanoparticlesProstatic HyperplasiaSilicon DioxideUltrasonic TherapyAnimalsApoptosisCell LineHumansMalePorosityRatsRats, Sprague-DawleyReactive Oxygen SpeciesCopperManganeseReactive Oxygen SpeciesSilicon Dioxidebenign prostatic hyperplasiamesoporous silica nanoparticlesoxeiptosissonodynamic therapyultra-minimally invasive therapy

Identifiers

PMID40911431
PMCPMC12447393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.